Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 0.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,422,566 shares of the company’s stock after selling 21,848 shares during the quarter. Wellington Management Group LLP’s holdings in Hims & Hers Health were worth $82,758,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership lifted its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. lifted its position in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in Hims & Hers Health in the fourth quarter valued at $41,104,000. Principal Financial Group Inc. grew its holdings in shares of Hims & Hers Health by 370.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock worth $33,024,000 after purchasing an additional 1,075,355 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth about $18,048,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 7.4 %

Shares of HIMS opened at $25.93 on Friday. The stock’s 50 day moving average is $39.82 and its two-hundred day moving average is $29.84. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The firm has a market capitalization of $5.76 billion, a PE ratio of 58.93 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Needham & Company LLC raised their price target on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Citigroup reiterated a “sell” rating and issued a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Piper Sandler raised their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 25th. Finally, Bank of America upped their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $37.31.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. The trade was a 61.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Irene Becklund sold 2,203 shares of the firm’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the transaction, the insider now directly owns 8,007 shares of the company’s stock, valued at $230,441.46. The trade was a 21.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,078,738 shares of company stock valued at $38,386,521 in the last ninety days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.